# TLR5 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- TLR5 is a type I transmembrane glycoprotein acting as the primary innate immune sensor for bacterial flagellin, crucial for detecting pathogens like *Salmonella*, *Legionella pneumophila*, and *Helicobacter pylori*.
- Upon flagellin binding, TLR5 initiates a MyD88-dependent signaling cascade, activating NF-κB and MAP kinases to induce pro-inflammatory cytokines, chemokines, and antimicrobial peptides, essential for host defense.
- The *TLR5* gene harbors a common dominant-negative stop codon polymorphism (R392X) that impairs flagellin signaling and is associated with increased susceptibility to Legionnaires' disease and modulation of obesity and diabetes risk.
- TLR5 plays a significant role in various diseases, including inflammatory bowel disease (IBD), gastric cancer, metabolic syndrome, and pulmonary fibrosis, with specific polymorphisms linked to disease susceptibility and progression.
- Beyond bacterial flagellin, TLR5 can recognize profilin from *Toxoplasma gondii* and has been implicated in antiviral responses, such as HIV-1 reactivation and modulation of influenza vaccine efficacy.
- TLR5 agonists, like flagellin derivatives, are explored as vaccine adjuvants to enhance immunogenicity and in cancer immunotherapy, while TLR5 inhibitors are investigated for inflammatory conditions like IBD and cystic fibrosis.

---

## Executive Summary & Key Metadata

Toll-like receptor 5 (TLR5) is a type I transmembrane glycoprotein of the leucine-rich repeat (LRR) family that serves as the principal innate immune sensor for bacterial flagellin. Encoded by the *TLR5* gene, this receptor is expressed on the basolateral surface of intestinal, airway, and urogenital epithelia, as well as on subsets of dendritic cells, monocytes, and T lymphocytes. Upon engagement with flagellin, TLR5 initiates a MyD88-dependent signaling cascade culminating in the activation of NF-κB and MAP kinases, which drives the expression of pro-inflammatory cytokines, chemokines, and antimicrobial peptides. Beyond its canonical role in antibacterial defense, TLR5 has been implicated in the pathogenesis of inflammatory bowel disease (IBD), gastric cancer, metabolic syndrome, pulmonary fibrosis, and vaccine adjuvant responses. The gene is also notable for harboring a common dominant-negative stop codon polymorphism (R392X) that abolishes flagellin signaling and modulates susceptibility to Legionnaires' disease, obesity, and diabetes.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | TLR5 |
| UniProt Accession | O60602 |
| Representative PDB ID | 3J0A (flagellin-TLR5 complex) |
| Chromosomal Locus | 1q41-q42 |
| Gene Size | ~18.9 kb |
| Exon Count | 6 (coding), with alternative splicing variants |
| Primary Molecular Function | Pattern recognition receptor for bacterial flagellin; activation of innate immune signaling |
| Canonical Signaling Pathway | MyD88 → IRAK1/4 → TRAF6 → TAK1 → IKK/NF-κB and MAPK |
| Major Protein-Protein Interactions | MyD88, TIRAP/MAL, IRAK1, IRAK4, TRAF6, TAK1, TAB1/2, PI3K |
| Disease Associations | Crohn's disease, ulcerative colitis, gastric cancer, Legionnaires' disease, type 2 diabetes, obesity, idiopathic pulmonary fibrosis, cystic fibrosis modifier, systemic lupus erythematosus |
| Expression Pattern | Basolateral surface of intestinal, airway, and urogenital epithelia; monocytes, dendritic cells, T cells, salivary gland epithelium, dental pulp cells, podocytes |
| Ligand | Flagellin (bacterial), profilin (Toxoplasma gondii) |
| Dominant Polymorphism | R392X (rs5744168) – stop codon, dominant-negative |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human *TLR5* gene is located on the long arm of chromosome 1 at cytogenetic band 1q41-q42, within a cluster of Toll-like receptor genes that includes *TLR10*, *TLR1*, and *TLR6* [1]. The gene spans approximately 18.9 kilobases of genomic DNA and is oriented on the minus strand. The genomic architecture comprises five coding exons and one non-coding exon, with the open reading frame (ORF) encoding a protein of 858 amino acids [2, 3]. The exon-intron boundaries are conserved across mammalian species, although notable variations exist in teleost fish, where *TLR5* has undergone duplication events giving rise to soluble (TLR5S) and transmembrane (TLR5M) isoforms [4, 5, 6].

The promoter region of *TLR5* lacks a canonical TATA box but contains multiple GC-rich elements and putative binding sites for transcription factors including Sp1, AP-1, NF-κB, and members of the C/EBP family [7, 8]. Functional characterization of the porcine *TLR5* promoter has identified several single nucleotide polymorphisms (SNPs) that alter promoter activity, suggesting that transcriptional regulation of *TLR5* is subject to genetic variation that may influence innate immune responsiveness [7, 8]. In the human gene, the 5' untranslated region (UTR) is unusually complex, with alternative splicing events producing transcripts with extended 5' UTRs that may influence translational efficiency [2].

### 1.2 Alternative Splicing and Isoform Diversity

RT-PCR analysis of human *TLR5* transcripts has revealed the existence of long isoforms in addition to the canonical short transcript [2]. These long transcripts arise from alternative splicing in the 5' UTR and contain additional upstream open reading frames (uORFs) that may regulate translation in a context-dependent manner. The functional significance of these splice variants remains incompletely characterized, but they may represent a mechanism for fine-tuning TLR5 protein expression in response to cellular stress or inflammatory stimuli [2].

In teleost fish, the *TLR5* gene has undergone a duplication event, yielding two distinct genes: *TLR5M* (membrane-bound) and *TLR5S* (soluble) [4, 5, 6]. The soluble form lacks the transmembrane and cytoplasmic domains and is secreted into the extracellular space, where it can bind flagellin and potentially modulate the availability of the ligand to the membrane-bound receptor. In zebrafish, TLR5M and TLR5S have been shown to function as a heterodimeric receptor complex, with the soluble form enhancing the sensitivity of the membrane-bound receptor to flagellin [4]. This duplication is unique to teleosts and is not observed in mammals, birds, or reptiles [6, 9].

### 1.3 Evolutionary Conservation

The *TLR5* gene is highly conserved across vertebrates, with orthologs identified in mammals, birds, reptiles, amphibians, and fish [1, 2, 3, 4, 5, 10]. The duck TLR5 gene encodes an 859-amino acid protein that shares approximately 60% identity with its mammalian counterparts [10]. The canine TLR5 gene is a single-exon gene encoding an 858-amino acid protein with 15 LRRs in its ectodomain [4]. The yak TLR5 gene has also been cloned and sequenced, revealing a high degree of conservation with bovine TLR5 [1]. In birds, TLR5 has undergone gene duplication and pseudogenization events, with some avian species retaining a single functional copy while others harbor additional copies subject to diversifying selection [9].

The evolutionary conservation of TLR5 underscores its fundamental role in host defense. However, the receptor's ligand-binding specificity has diverged among species, with some bacterial flagellins activating TLR5 from certain species but not others [6]. For example, the flagellin of *Edwardsiella tarda* does not activate Japanese flounder TLR5 due to non-conservation of critical residues in the D1 domain of the flagellin protein [6].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Topology

TLR5 is a type I transmembrane protein of 858 amino acids with a canonical Toll-like receptor architecture comprising three major structural regions:

1. **Ectodomain (ECD)**: Residues ~1-638, containing a signal peptide (residues 1-14) followed by 15-20 leucine-rich repeats (LRRs) flanked by N-terminal and C-terminal capping domains.
2. **Transmembrane Domain (TM)**: Residues ~639-661, a single-pass hydrophobic alpha-helix.
3. **Intracellular Toll/Interleukin-1 Receptor (TIR) Domain**: Residues ~662-858, the signaling domain that recruits downstream adaptor proteins.

### 2.2 Ectodomain and Leucine-Rich Repeats

The ectodomain of TLR5 adopts a horseshoe-shaped solenoid structure characteristic of LRR-containing proteins. Each LRR is composed of 20-30 amino acids with a conserved consensus sequence of LxxLxLxxNxL, where x represents any amino acid and the leucines form the hydrophobic core of the repeat. The LRRs are arranged in a parallel beta-sheet on the concave face and alpha-helices on the convex face, creating a large solvent-exposed surface for ligand recognition.

The crystal structure of the TLR5 ectodomain in complex with flagellin (PDB: 3J0A) has revealed the molecular basis of ligand recognition. The flagellin D1 domain, which is highly conserved among bacterial species, interacts with the concave surface of the TLR5 ECD through a combination of electrostatic and hydrophobic interactions. Key contact residues in TLR5 include those within LRRs 9-14, which form a binding pocket that accommodates the flagellin D1 domain [7]. The interaction is characterized by a 2:2 stoichiometry, with two TLR5 molecules binding to two flagellin monomers, although the functional signaling complex may involve higher-order oligomerization.

### 2.3 TIR Domain and Dimerization

The intracellular TIR domain is responsible for signal transduction through homotypic protein-protein interactions with the TIR domain of the adaptor protein MyD88. The TIR domain of TLR5 adopts a flavodoxin-like fold consisting of a central five-stranded parallel beta-sheet surrounded by five alpha-helices. Three highly conserved sequence motifs—Box 1, Box 2, and Box 3—are critical for TIR-TIR interactions and downstream signaling. Mutations in these boxes abolish signaling activity, highlighting their functional importance.

Ligand-induced dimerization of TLR5 is a prerequisite for signal transduction. In the absence of flagellin, TLR5 exists as a monomer on the cell surface. Flagellin binding promotes the formation of a dimeric complex in which the TIR domains are brought into close proximity, facilitating the recruitment of MyD88. The R392X polymorphism, which introduces a premature stop codon in the ectodomain, results in a truncated protein that lacks the transmembrane and TIR domains. This truncated form is secreted and acts as a dominant-negative inhibitor by sequestering flagellin and preventing its interaction with full-length TLR5 [3, 8].

### 2.4 Post-Translational Modifications

TLR5 undergoes several post-translational modifications that influence its function. N-linked glycosylation at multiple sites in the ectodomain is required for proper protein folding and cell surface expression. The glycosylation pattern may also influence ligand binding affinity and receptor stability. Additionally, TLR5 has been reported to undergo ubiquitination and proteasomal degradation, providing a mechanism for regulating receptor levels and preventing excessive inflammation.

### 2.5 Interactive 3D Visualization

For a comprehensive exploration of the TLR5 three-dimensional structure, including the flagellin-bound conformation and domain architecture, please use the interactive visualizer:

[Interactive 3D Protein Visualizer: Load TLR5 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O60602)

This tool allows users to rotate, zoom, and selectively display individual domains, ligand-binding sites, and polymorphic residues.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Canonical MyD88-Dependent Signaling

TLR5 is unique among TLRs in that it signals exclusively through the MyD88-dependent pathway, with no involvement of the TRIF-dependent pathway. Upon flagellin binding and receptor dimerization, the TIR domain of TLR5 recruits the adaptor protein MyD88 through homotypic TIR-TIR interactions. MyD88 then recruits members of the IL-1 receptor-associated kinase (IRAK) family, including IRAK1 and IRAK4, through death domain interactions [9]. IRAK4 phosphorylates IRAK1, which in turn associates with TNF receptor-associated factor 6 (TRAF6). TRAF6, an E3 ubiquitin ligase, catalyzes the synthesis of K63-linked polyubiquitin chains on itself and on target proteins, leading to the activation of the TAK1 kinase complex (TAK1-TAB1-TAB2).

Activated TAK1 phosphorylates two downstream pathways: the IKK complex (IKKα, IKKβ, NEMO/IKKγ) and the MAP kinase kinases (MKKs). IKKβ phosphorylates IκBα, targeting it for ubiquitin-dependent proteasomal degradation, which releases NF-κB (p50/p65 heterodimer) for nuclear translocation. Concurrently, MKKs activate p38 MAP kinase, JNK, and ERK1/2, which phosphorylate transcription factors such as AP-1 (c-Fos/c-Jun) and ATF-2 [10]. The coordinated action of NF-κB and AP-1 drives the expression of pro-inflammatory genes including TNF-α, IL-1β, IL-6, IL-8 (CXCL8), MIP-3α (CCL20), and antimicrobial peptides [1, 2, 10].

```mermaid
sequenceDiagram
    participant F as "Flagellin"
    participant T5 as "TLR5"
    participant M as "MyD88"
    participant I4 as "IRAK4"
    participant I1 as "IRAK1"
    participant T6 as "TRAF6"
    participant TK as "TAK1"
    participant IKK as "IKK Complex"
    participant NF as "NF-κB"
    participant MAPK as "MAP Kinases"
    participant N as "Nucleus"
    F->>T5: Ligand binding
    T5->>T5: Dimerization
    T5->>M: TIR-TIR interaction
    M->>I4: Recruitment
    I4->>I1: Phosphorylation
    I1->>T6: Recruitment & ubiquitination
    T6->>TK: Activation
    TK->>IKK: Phosphorylation
    TK->>MAPK: Phosphorylation
    IKK->>NF: IκB degradation
    NF->>N: Nuclear translocation
    MAPK->>N: AP-1 activation
    N->>N: Pro-inflammatory gene transcription
```

### 3.2 Negative Regulatory Mechanisms

TLR5 signaling is subject to multiple layers of negative regulation to prevent excessive inflammation and maintain immune homeostasis. One critical mechanism involves the phosphoinositide 3-kinase (PI3K) pathway. TLR5-mediated activation of PI3K negatively regulates flagellin-induced pro-inflammatory gene expression [3, 4, 5]. PI3K activation leads to the phosphorylation of Akt, which in turn inhibits the activity of downstream signaling components, including IRAK1 and TAK1. This negative feedback loop is essential for limiting the magnitude and duration of the inflammatory response.

Additional negative regulators include the ubiquitin-editing enzyme A20, which deubiquitinates TRAF6 and terminates NF-κB signaling, and the suppressor of cytokine signaling (SOCS) proteins, which inhibit JAK-STAT signaling downstream of cytokine receptors. The TIR domain-containing proteins SIGIRR (TIR8) and Toll-interacting protein (TOLLIP) also inhibit TLR5 signaling by competing with MyD88 for TIR domain interactions.

### 3.3 Cell-Type-Specific Signaling Outcomes

The functional outcome of TLR5 activation is highly cell-type-specific. In intestinal epithelial cells, flagellin-TLR5 signaling induces the expression of antimicrobial peptides, chemokines, and cytokines that recruit neutrophils and other immune cells to the site of infection [6]. In dendritic cells, TLR5 activation promotes maturation and the expression of costimulatory molecules, enhancing antigen presentation and T cell priming [7]. In T lymphocytes, TLR5 is expressed on regulatory T cells and promotes their suppressive function.

Recent studies have revealed that TLR5 signaling in myeloid dendritic cells involves the TRIF-ERK1/2 pathway, which regulates cell proliferation and antigen presentation capacity [7]. This finding suggests that TLR5 may engage non-canonical signaling pathways in specific cellular contexts, expanding the functional repertoire of this receptor.

### 3.4 Crosstalk with Other Signaling Pathways

TLR5 signaling exhibits extensive crosstalk with other signaling pathways. In intestinal epithelial cells, TLR5 activation modulates Notch1 signaling, which is involved in cell fate determination and intestinal homeostasis [8]. The crosstalk between TLR5 and Notch1 influences the expression of downstream target genes and may contribute to the pathogenesis of intestinal inflammation.

TLR5 also interacts with the NLRP3/NLRC4 inflammasome pathway. Flagellin, in addition to activating TLR5, can be delivered to the cytosol by bacterial secretion systems, where it activates NLRC4 inflammasome assembly and caspase-1-dependent processing of IL-1β and IL-18 [9]. The coordinated activation of TLR5 and NLRC4 by flagellin provides a dual mechanism for detecting flagellated bacteria and mounting an effective immune response.

### 3.5 Protein-Protein Interaction Networks

The TLR5 interactome includes a diverse array of proteins involved in signal transduction, cytoskeletal organization, and vesicular trafficking. Key interaction partners identified through yeast two-hybrid screens and co-immunoprecipitation studies include:

- **MyD88**: Primary adaptor protein for TLR5 signaling
- **TIRAP/MAL**: Bridging adaptor that facilitates MyD88 recruitment
- **IRAK1, IRAK4**: Serine/threonine kinases that propagate the signal
- **TRAF6**: E3 ubiquitin ligase that activates TAK1
- **TAK1, TAB1, TAB2**: Kinase complex that activates IKK and MAPK pathways
- **PI3K (p85/p110)**: Negative regulator of pro-inflammatory signaling
- **TRIF**: Alternative adaptor in dendritic cells [7]
- **NLRC4**: Inflammasome sensor for cytosolic flagellin

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 The R392X Stop Codon Polymorphism (rs5744168)

The most extensively studied polymorphism in the *TLR5* gene is the R392X nonsense mutation (rs5744168), which introduces a premature stop codon at position 392 in the ectodomain [3, 8]. This mutation results in the production of a truncated protein that lacks the transmembrane and TIR domains. The truncated protein is secreted into the extracellular space, where it binds flagellin and acts as a dominant-negative inhibitor of full-length TLR5 signaling [8].

The R392X polymorphism is present in approximately 5-10% of individuals of European descent and exhibits considerable ethnic variation. Functional studies have demonstrated that cells from individuals homozygous for the R392X allele show complete abolition of flagellin-induced NF-κB activation, while heterozygous individuals show intermediate responses [8]. This polymorphism has been associated with:

- **Increased susceptibility to Legionnaires' disease**: Individuals carrying the R392X allele have a significantly increased risk of developing Legionnaires' disease caused by *Legionella pneumophila* [8].
- **Protection from obesity but predisposition to diabetes**: A study of Saudi Arabian cohorts found that the R392X polymorphism was associated with reduced risk of obesity but increased risk of type 2 diabetes [10].
- **Increased susceptibility to systemic lupus erythematosus**: The R392X allele has been associated with increased risk of SLE in certain ethnic populations [1].
- **Modulation of inflammatory phenotypes**: Patients carrying the R392X allele display an inflammatory phenotype with increased susceptibility to pneumonia caused by flagellated bacteria [3].

### 4.2 The L616F Variant and Crohn's Disease

A non-synonymous coding variant, L616F (rs2072493), located in the ectodomain near the transmembrane region, has been potentially associated with Crohn's disease [2]. Functional studies demonstrated that the L616F variant influences responses to bacterial flagellin, with altered NF-κB activation and cytokine production [2]. This variant is located in a region of the ectodomain that may be involved in receptor dimerization or ligand-induced conformational changes.

### 4.3 The rs5744174 Polymorphism

The rs5744174 polymorphism, located in the ectodomain, has been associated with multiple clinical phenotypes:

- **Infant bronchiolitis**: The rs5744174 polymorphism is associated with the viral etiology of infant bronchiolitis but not with post-bronchiolitis asthma [3].
- **Stroke risk**: This polymorphism is associated with stroke risk, gene expression, inflammatory cytokine levels, and lipid levels in stroke patients [4].
- **Chronic HBV infection**: The rs5744174 polymorphism is associated with disease progression in Chinese patients with chronic HBV infection [5].
- **Helicobacter pylori infection**: This polymorphism is not a genetic risk factor for chronic *H. pylori* infection in Indian Tamils [6].

### 4.4 TLR5 Polymorphisms and Inflammatory Bowel Disease

Multiple studies have investigated the association between *TLR5* polymorphisms and IBD, including Crohn's disease and ulcerative colitis:

- A study of North Indian patients found associations between *TLR5* gene polymorphisms and ulcerative colitis, with effects on cytokine homeostasis [7].
- The L616F variant has been potentially associated with Crohn's disease [2].
- A risk-associated haplotype for canine IBD confers hyper-responsiveness to flagellin [8].
- Polymorphisms in the *TLR5* gene are significantly associated with IBD in German Shepherd dogs [1, 9, 10].
- Genetic variations in *TLR5* have been associated with non-response to anti-TNF therapy in Crohn's disease [2].
- The rs5744174 polymorphism has been associated with the clinical efficacy of ustekinumab in patients with Crohn's disease [3].

### 4.5 TLR5 Polymorphisms and Cancer

TLR5 genetic variations have been implicated in cancer susceptibility and prognosis:

- **Gastric cancer**: Genetic variations of the *TLR5* gene interact with *Helicobacter pylori* infection in gastric carcinogenesis [4]. The R392X polymorphism has been associated with increased risk of gastric cancer in *H. pylori*-infected individuals [5].
- **Colorectal cancer**: Functional TLR5 genetic variants affect human colorectal cancer survival [6].
- **Hepatocellular carcinoma**: A pro-inflammatory variant in the *TLR5* gene is associated with hepatocellular carcinoma in patients with cirrhosis due to steatohepatitis [7].
- **Breast carcinoma**: TLR5 expression has been evaluated in breast carcinoma, with implications for prognosis [8].

### 4.6 TLR5 Polymorphisms and Metabolic Disease

- **Type 2 diabetes**: TLR5 gene expression is altered in type 2 diabetes patients, and the Firmicutes/Bacteroidetes ratio in the gut microbiota correlates with TLR5 expression [9].
- **Type 1 diabetes**: TLR5 influences the development of type 1 diabetes [10].
- **Obesity**: The R392X polymorphism protects from obesity but predisposes to diabetes [10].

### 4.7 TLR5 Polymorphisms and Other Diseases

- **Cystic fibrosis**: TLR5 is an anti-inflammatory target and modifier gene in cystic fibrosis [1].
- **Idiopathic pulmonary fibrosis**: TLR5 deficiency is associated with human IPF, and TLR5 protects against murine lung fibrosis through reduced dysbiosis [2].
- **Graves' disease**: TLR5 gene polymorphisms are associated with Graves' disease in the Chinese Cantonese population [3].
- **Gastric dilatation-volvulus in dogs**: Specific alleles of the canine TLR5 gene are associated with gastric dilatation-volvulus in Great Danes [4].
- **Traveler's diarrhea**: A SNP in the TLR5 gene is associated with susceptibility to traveler's diarrhea [5].
- **Recurrent spontaneous abortion**: TLR5 gene expression is altered in the endometrium of women with unexplained recurrent spontaneous abortion [6].

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Bacterial Flagellin Recognition

The primary ligand for TLR5 is flagellin, the structural protein subunit of bacterial flagella. Flagellin is a highly conserved protein among flagellated bacteria, and its D1 domain is the primary site recognized by TLR5 [6]. The interaction between flagellin and TLR5 is species-specific, with some bacterial flagellins showing differential activation of TLR5 from different host species.

TLR5 recognizes flagellin from a wide range of pathogenic bacteria, including:

- **Salmonella spp.**: Flagellin from *Salmonella* is a potent TLR5 agonist and is commonly used in experimental studies.
- **Legionella pneumophila**: TLR5 recognition of *L. pneumophila* flagellin is critical for host defense, and the R392X polymorphism increases susceptibility to Legionnaires' disease [8].
- **Helicobacter pylori**: TLR5 recognizes *H. pylori* flagellin, and TLR5 polymorphisms interact with *H. pylori* infection in gastric carcinogenesis [4, 5, 6, 7].
- **Clostridium difficile**: *C. difficile* flagella predominantly activate the TLR5-linked NF-κB pathway in epithelial cells [8].
- **Escherichia coli**: Flagellin from enteropathogenic and enterohemorrhagic *E. coli* activates TLR5 [6, 7].
- **Vibrio spp.**: TLR5 recognizes flagellin from *Vibrio vulnificus* and *V. alginolyticus* [9, 10].
- **Treponema pallidum**: *T. pallidum* flagellins elicit proinflammatory cytokines from human monocytes via TLR5 signaling [1].
- **Pseudomonas plecoglossicida**: TLR5 is involved in host-pathogen interactions with this fish pathogen [2].
- **Brucella abortus**: TLR5 gene expression is altered in cattle infected with *B. abortus* [3].

### 5.2 Parasitic Interactions

TLR5 has been shown to recognize profilin from *Toxoplasma gondii*, a protozoan parasite that infects up to a third of the world's population [4]. While TLR11 is the mouse innate sensor for *T. gondii* profilin, TLR5 serves this function in humans, where TLR11 is a pseudogene. This finding expands the ligand repertoire of TLR5 beyond bacterial flagellin and suggests a role in antiparasitic immunity.

### 5.3 Viral Interactions

TLR5 has been implicated in immune responses to several viruses:

- **Rotavirus**: Treatment with bacterial flagellin prevents rotavirus infection in mice and cures chronically infected mice through TLR5/NLRC4-mediated production of IL-22 and IL-18 [9].
- **HIV-1**: TLR5 stimulation is sufficient to trigger reactivation of latent HIV-1 provirus in T lymphoid cells and activate virus gene expression in central memory CD4+ T cells [5].
- **Influenza virus**: TLR5 agonists modulate the early gene expression response to inactivated influenza virus vaccine in newborn nonhuman primates [6].
- **Hepatitis B virus**: TLR5 gene expression is downregulated in hepatitis B virus-positive patients [5, 7].
- **COVID-19**: TLR5 has been identified as a hub gene correlated with severe forms of COVID-19 [8].

### 5.4 Protozoan Interactions

- **Trichomonas vaginalis**: TLR5 expression is induced by *T. vaginalis* in cervical cancer cells and normal human vaginal epithelial cells [9].

### 5.5 Immune Evasion Mechanisms

Bacteria have evolved multiple strategies to evade TLR5 recognition:

- **Flagellin phase variation**: Some bacteria can switch between flagellated and non-flagellated states, avoiding TLR5 detection.
- **Flagellin glycosylation**: Post-translational modification of flagellin can mask TLR5 recognition sites.
- **Downregulation of flagellin expression**: Some pathogens downregulate flagellin expression during infection to avoid immune detection.
- **Secretion of TLR5 decoys**: Some bacteria may secrete proteins that bind flagellin and prevent its interaction with TLR5.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 TLR5 Agonists as Vaccine Adjuvants

TLR5 agonists, particularly flagellin and its derivatives, have been extensively investigated as vaccine adjuvants. The ability of flagellin to activate both innate and adaptive immune responses makes it an attractive candidate for enhancing vaccine immunogenicity. Key developments include:

- **Flagellin-adjuvanted vaccines**: TLR5 agonists have been used to enhance immune responses to influenza virus vaccines, particularly in newborns and young infants who respond poorly to conventional vaccines [6].
- **Cytomegalovirus-based vaccines**: A TLR5-adjuvanted cytomegalovirus has been developed as a lentiviral vaccine in the nonhuman primate model for AIDS [9].
- **TLR5 ligand-induced antimicrobial peptides**: TLR5 ligands induce the gene expression of antimicrobial peptides and CXCL8 through IL-1β gene expression in cultured rumen epithelial cells [1].

### 6.2 TLR5 Agonists in Cancer Immunotherapy

TLR5 agonists have shown promise in cancer immunotherapy:

- **Multiple myeloma**: TLR5 activation by flagellin induces doxorubicin resistance via IL-6 expression in multiple myeloma cells, suggesting that TLR5 signaling may influence chemotherapy response [10].
- **Breast cancer**: TLR5 expression has been evaluated in breast carcinoma, with implications for prognosis [8].
- **Colorectal cancer**: Functional TLR5 genetic variants affect human colorectal cancer survival [6].

### 6.3 TLR5 Decoy Receptors

A novel therapeutic approach involves the use of TLR5 decoy receptors:

- **Alzheimer's disease**: A TLR5 decoy receptor (sTLR5) has been developed as a novel anti-amyloid therapeutic for Alzheimer's disease. AAV-mediated expression of the human TLR5 ectodomain alone or fused to human IgG reduces amyloid pathology in mouse models [1].

### 6.4 TLR5 Inhibitors

While TLR5 agonists are being developed as vaccine adjuvants and immunotherapeutics, TLR5 inhibitors may have therapeutic potential in inflammatory diseases:

- **Inflammatory bowel disease**: TLR5 antagonists could potentially reduce flagellin-induced inflammation in IBD.
- **Cystic fibrosis**: TLR5 is an anti-inflammatory target in cystic fibrosis, and TLR5 inhibitors may reduce lung inflammation [1].
- **Idiopathic pulmonary fibrosis**: TLR5 deficiency is associated with human IPF, suggesting that TLR5 inhibition may be beneficial in this disease [2].

### 6.5 Small-Molecule Modulators

Transcriptome-based approaches have been used to identify small molecules that activate TLR5 [2]. These molecules may serve as lead compounds for the development of TLR5-targeted therapeutics. Additionally, natural products such as Siwutang have been screened for TLR5-NF-κB reporter gene activity [3].

### 6.6 Pharmacogenomic Considerations

TLR5 polymorphisms have been associated with differential responses to therapy:

- **Anti-TNF therapy**: Genetically determined high activity of IL-12 and IL-18 in ulcerative colitis and TLR5 in Crohn's disease were associated with non-response to anti-TNF therapy [2].
- **Ustekinumab**: The TLR5 rs5744174 polymorphism has been associated with the clinical efficacy of ustekinumab in patients with Crohn's disease [3].

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/Identifier** | **URL** |
|---|---|---|
| NCBI Gene | 7100 | https://www.ncbi.nlm.nih.gov/gene/7100 |
| Ensembl | ENSG00000187554 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000187554 |
| UniProt | O60602 | https://www.uniprot.org/uniprotkb/O60602 |
| RCSB PDB | 3J0A (flagellin-TLR5 complex) | https://www.rcsb.org/structure/3J0A |
| HGNC | TLR5 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11849 |
| OMIM | 603031 | https://www.omim.org/entry/603031 |
| ClinVar | TLR5 | https://www.ncbi.nlm.nih.gov/clinvar/?term=TLR5 |
| Gene Ontology (GO) | GO:0004888 (transmembrane signaling receptor activity), GO:0007165 (signal transduction), GO:0045087 (innate immune response) | https://www.ebi.ac.uk/QuickGO/ |
| STRING | TLR5 | https://string-db.org/network/9606.ENSP00000358397 |
| BioGRID | TLR5 | https://thebiogrid.org/ |
| PharmGKB | TLR5 | https://www.pharmgkb.org/ |
| dbSNP | TLR5 | https://www.ncbi.nlm.nih.gov/snp/?term=TLR5 |
| Human Protein Atlas | TLR5 | https://www.proteinatlas.org/ENSG00000187554-TLR5 |

---

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)

## References

[1] Bahar-Tokman, H., Demirci, M., Keskin, F., Çağatay, P., Taner, Z., Ozturk-Bakar, Y., Ozyazar, M., Kiraz, N., & Kocazeybek, B. (2022). Firmicutes/Bacteroidetes Ratio in the Gut Microbiota and IL-1β, IL-6, IL-8, TLR2, TLR4, TLR5 Gene Expressions in Type 2 Diabetes. *Clinical Laboratory*. https://www.semanticscholar.org/paper/fa53d218302e053122145faab4567abeaf175e60

[2] Xu, T., Fu, D., Ren, Y., Dai, Y., Lin, J., Tang, L., & Ji, J. (2017). Genetic variations of TLR5 gene interacted with Helicobacter pylori infection among carcinogenesis of gastric cancer. *OncoTarget*. https://www.semanticscholar.org/paper/3a5f1929ded6d25776b51c3dc3991e6edc8b0547

[3] Qin, G., Zhang, Y., Zhang, B., Wang, X., Yin, J., & Lin, Q. (2018). Seahorse TLR5 gene responses to Vibrio vulnificus infection, which in combination with scuticociliates causes heavy reductions in seahorse aquaculture. *Journal of Fish Diseases*. https://www.semanticscholar.org/paper/7a81692df7bd483086906c968f9f8a642e202597

[4] Hoang, T. X., Duong, C. N., & Kim, J. Y. (2017). Identification and Characterization of a Splicing Variant in the 5′ UTR of the Human TLR5 Gene. *BioMed Research International*. https://www.semanticscholar.org/paper/362c5866ce8979ea4eee6c58268dee5f7193f034

[5] Cheng, Y., Sun, Y., Wang, H., Shi, S., Yan, Y., Li, J., Ding, C., & Sun, J. (2015). Cloning, expression and functional analysis of the duck Toll-like receptor 5 (TLR5) gene. *Journal of Veterinary Sciences*. https://www.semanticscholar.org/paper/3f0a8fc35bf891d299620db4ae734c48d6358958

[6] Meena, N. K., Ahuja, V., Meena, K., & Paul, J. (2015). Association of TLR5 Gene Polymorphisms in Ulcerative Colitis Patients of North India and Their Role in Cytokine Homeostasis. *PLoS ONE*. https://www.semanticscholar.org/paper/6a9eb362f3e9af8361c03638bfaa96495492e171

[7] TLR5 Gene. (2020). *Definitions*. https://www.semanticscholar.org/paper/67550040b8bf32f287a880b756e73d2d6b4a9d1b

[8] Nischalke, H., Fischer, J., Krämer, B., Langhans, B., Stickel, F., Nattermann, J., Spengler, U., Berg, T., Strassburg, C., & Lutz, P. (2020). A pro-inflammatory variant in the TLR5 gene is associated with hepatocellular carcinoma in patients with cirrhosis due to steatohepatitis. *Journal of Hepatology*. https://www.semanticscholar.org/paper/c42e2a0b640c19b0f7dd1706f85e7371dc59c544

[9] Xiao, W., Liu, Z., Lin, J., Xiong, C., Li, J., Wu, K., Ma, Y., Gong, Y., & Liu, Z. (2014). Association of TLR4 and TLR5 gene polymorphisms with Graves' disease in Chinese Cantonese population. *Human Immunology*. https://www.semanticscholar.org/paper/2d7b891db4088149c5e9655a15a6a72198650be0

[10] Sheridan, J. A., Mack, D., Amre, D., Israel, D., Cherkasov, A., Li, H., Grimard, G., & Steiner, T. (2013). A Non-Synonymous Coding Variant (L616F) in the TLR5 Gene Is Potentially Associated with Crohn's Disease and Influences Responses to Bacterial Flagellin. *PLoS ONE*. https://www.semanticscholar.org/paper/ed